
Please try another search
By Anirban Sen and David Carnevali
(Reuters) -U.S. scientific instruments maker Thermo Fisher Scientific Inc (NYSE:TMO) and South Korea's Celltrion Inc are among those competing to acquire the biopharma solutions business of medical device maker Baxter International Inc (NYSE:BAX), according to people familiar with the matter.
The divestment, which the sources said could fetch more than $4 billion, would help Baxter pay down debt following its $10.5 billion acquisition of medical device maker Hill-Rom (NYSE:HRC) Holdings in 2021. Baxter, which has a market value of $19 billion, had total debt of $16.6 billion as of the end of December.
Private equity firms, including KKR & Co (NYSE:KKR) and Carlyle Group (NASDAQ:CG), have also expressed interest in the Baxter business, the sources said. Other bidders could still emerge, they added.
The sources requested anonymity because the matter is confidential. Baxter, Thermo Fisher and KKR declined to comment. Celltrion and Carlyle did not immediately respond to requests for comment.
Baxter said in January it was exploring alternatives for its biopharma solutions business and would also spin off its kidney care units.
The Deerfield, Illinois-based company focuses on areas such as critical care, surgical products, nutrition and pharmaceutical equipment.
Baxter's biopharma solutions unit supports drugmakers in the formulation, development and commercialization of drugs typically given by infusion or injection, such as biologics and vaccines.
Thermo Fisher, one of the world's largest suppliers of scientific equipment, has been making acquisitions in recent years to expand its offerings in contract research and manufacturing, including a $5.2 billion purchase of Patheon NV in 2017 and a $17.4 billion takeover of PPD (NASDAQ:PPD) Inc in 2021.
Celltrion, whose co-founder and chairman Seo Jung-jin is South Korea's richest person according to Forbes, is a biopharmaceutical company that also has a contract research and manufacturing arm.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.